1. Introduction {#sec1}
===============

The ongoing pandemic coronavirus disease outbreak (COVID-2019), stemming from the beta coronavirus class (SARS-CoV-2) causing severe acute respiratory syndrome (SARS), has created a global health emergency in \>200 countries around the globe ([@bib28]; [@bib49]). SARS-CoV-2, a novel coronavirus strain belonging to the *Sarbecovirus* subgenus (genus *Betacoronavirus*, family *Coronaviridae*) had first appeared in late 2019, in Wuhan, China infecting a large number of hosts (\>3.1 million people) with a mortality rate of ≥3.6% ([@bib51]; [@bib7]). Such putative etiopathogenic agents associated with the zoonotic viral transmission pathways are responsible for respiratory (viral pneumonia) and gastro-intestinal infections leading to multiple organ failure in infected people or patients having co-morbidities. Till date no therapeutic drug has been discovered for the treatment of SARS-CoV-2 infection, though the importance of monoclonal antibodies, protease and helicase inhibitors and interferons (IFNs-α) treatments have been highlighted in a handful of literature ([@bib20]; [@bib68]; [@bib56]). Development of drug-resistant strains, host cell toxicity/target specific actions, costs associated with the serological diagnosis and therapeutics limit the widespread application of synthetic drugs (nucleoside analogs) ([@bib56]; [@bib68]).

Harnessing the potential of nanobiotechnology in the biomedical science, development of engineered nanostructured materials/nanomedicines may lead to better drug delivery, advanced therapeutics and medical diagnostics at nanoscale. In recent years, with the advancement of clinical practices, the use of metal (gold, silver, zinc and copper) nanoparticles in magnetic immunoassay, viral diagnostics and microfluidic technology has driven the researchers to explore the potential of nanotherapeutics ([@bib48]; [@bib20]). [@bib44] and [@bib2] have investigated the multi-strain inhibition of SARS coronavirus (SARS-CoV), herpes simplex virus 1 (HSV-1) and human immunodeficiency virus (HIV of T-cells) by sulfonated nanoparticles binding. They have reported that small particle size, tunable surface charges, biomimetic properties, faster encapsulation have made the engineered nanoparticles smart and stable colloidal carriers for the delivery of genes and drugs. The mode of action of functionalized nanoparticles can be explained by their covalent linkages with biological substrates such as peptides, proteins, antibodies and nucleic acids. Some researchers have reported virus-nanoparticles electrostatic nonspecific interactions elsewhere (i.e. influenza A (H5N1)) strain inhibition) ([@bib3]; [@bib62]).

Nanoparticulate drug carriers through the cellular and mechanistic establishment crossed the membranes and with the help of capping agents such as sulfate polysaccharides/polymers undergo multivalent bond interactions with virus glycoproteins (i.e hemagglutinin (HA)) ([@bib4]; [@bib5]). Such surface proteins often act as a prime inducer of neutralizing antibodies as observed by [@bib6] and [@bib8], where antigenic determinants enable nucleocapsid to take entry into the host cells as reported for *in vitro* SARS-CoV. Inhibition of virus replication and the fusion between the viral and host cell endosomal membrane are often facilitated by some emerging nano-based technologies i.e. silver nano-rod array surface enhanced Raman spectroscopy (SERS) substrate, interferometric biosensor immunoassay ([@bib9]; [@bib10]; [@bib12]). The development of such biomolecular detectors enable the molecular binding of virus particles to target specific (antigen phase) antibodies (coated waveguide), which help in the fast and reliable detection of viral infections ([@bib38]; [@bib13]; [@bib14]).

Considering the high transmissibility (R~0~: ≤6.0) and low to moderate pathogenicity of SARS-CoV-2 (\<6%) compared to Middle East respiratory syndrome coronavirus (MERS-CoV) and SARS-CoV, the quest for clinical development of suitable antiviral nanotherapeutics is need of the hour ([@bib61]; [@bib49]; [@bib17]). Though, it is noteworthy to mention that R~0~ is not data specific to the COVID-19 disease rather it depends on the place and the behavior of the population. It is associated with social isolation, hygienic habits, among others, and the variation must occur in different ways ([@bib73]; [@bib45]). The drug development for antiviral treatment (of SARS-CoV-2) depends on several factors such as pharmacokinetics (drug properties), collateral acute/chronic side effects and spike proteins (S) arrangement of coronaviruses (virus properties). These can act as therapeutic targets to prevent the fusion of the virus to host cell via binding with host cell receptors. Trimeric scaffolds such as NSP10 (a viral transcription factor) used along with secondary antigens in vaccines for lung and lower respiratory tract infections. These are essential to nucleate and stabilize pseudo-subdomains of protein and peptide antigens, which are also responsible for cell infection and polycistronic expression that may help in the nano-based therapeutic vaccine development ([@bib16]; [@bib25]; [@bib19]).

Peginterferon α-2a/2b (Pegasys), IFN-α2b show excellent drug delivery actions against Hepatitis virus (c), whereas cationic/cross-linked nanoparticles (biodegradable polymers) such as m-polyethylene glycol (mPEG)--PLA, CLPM are found suitable for Hepatitis (B and C) virus infections. Synthetic and natural polymeric nanoparticles (PNPs) are widely used since the last decade for the effective control of pathogenic viruses based on their individual biochemical properties (immuno/biocompatibility, bio-distribution factors) ([Table 1](#tbl1){ref-type="table"} ). Low to zero toxicity profile, high stability against proteinase degradation, improved safety/efficacy profiles and good internalization properties make such nanozymes effective against chronic infectious diseases and also help in exerting their cytoprotective actions against cytopathic effect. Polymeric nanoparticles in hybridized forms have found their way in biomedical sectors as therapeutics and diagnostics of human adenovirus, influenza virus and HIV. Therefore, the widespread application of hybridized nanoformulation systems have been documented by [@bib36] and [@bib37], where functionalized DNAzyme along with cellular peptides encoding viral envelopes help in the knockdown of HSV-2, HVC and influenza A viruses. For the first time, the purpose of the present systematic review lays out the framework for: (a) developing a critical understanding of self-assembling metal nanoparticles targeting a variety of fusion proteins for vaccine development; (b) the spatial geometry (three fold symmetry axis) and radial distributions that drive the rapid antigen processing and render virucidal activity; (c) building up a deep insight for biomarkers research in both prophylactic and therapeutic approaches; (d) the critical assessment of nanoparticles as therapeutics and associated drug metabolism pathways (biodegradation).Table 1A summary of biocompatible nanomaterials (and antiviral nanopharmaceuticals) commonly used for biomedical drug delivery action as virucidal agents (Souce of data: [@bib77]; [@bib70]; [@bib44]; [@bib32]; [@bib23]; [@bib16]).Table 1NanocarriersTarget specific cellVirus typesMode of antiviral activityVirucidal action**AuNPs**BHK-21, HeLa-CD-LTR, Vero cellsHIN1, H3N2, HIV-1Binding with Peroxidase-mimic enzymes and viral gp120Immunization/viral detection**Immobilized AuNPs**C6/36, BALB/c miceH3N2, Dengue virus, H5N1Antibody mediated inhibitionViral detection**TiO**~**2**~**NPs**n.a.\*H3N2Viral capsid protein interactionInactivation of virus by photolysis**Modified TiO**~**2**~**NPs**MDCKH5N1, H1N1Viral surface protein interactionVirus inhibition/inactivation**AgNPs**Vero cellsH7N3Inhibit CD4-based bindingViral entry inhibition**Engineered AgNPs**Human\
RhabdomyosarcomaFeline Calicivirus, InfluenzaViral envelop ruptureViral replication deformation**SiNPs**Vero cellsPapilloma VirusCell mediated immune/nucleic acid inhibitionVirus detection**Mesoporous Si**HEK293THSV-1, 2Hinder viral attachmentViral entry inhibition**Fullerenes**n.a.Bacteriophage λViral capsid/envelop attachment and interactionVirus destabilization**Modified Fullerenes**SupT1HIV-1 (wild and resistant type)Impairing viral polyprotein/hinder Gag processingInhibition of virus entry**FeNPs**n.a.Zika virusViral envelop/protein bindingHost pathogen interaction**Engineered FeNPs**n.a.Bacteriophage MS2, H5N2Phosphatidylserine inhibit viral tropismViral detection/removal**Acid/basic Functionalized Nanotube**NCIH292H3N2Photoactivated mediated viral inhibition/destabilizationVirus inactivation**Metal functionalized Nanotube**Grass carpReovirusVP7/DNA mediated inhibitionImmunization**Carbon dots**PK-15, MARC-145RSV, Pseudorabies virusType I interferon production inhibitedViral inhibition**Graphene oxide (GO)**Vero cellsPorcine epidemic diarrhea virusNegative single layered sharp edged particle interaction with virusViral entry hindrance**Polystyrene NPs**n.a.HIV-1viral\
gp120 antigen binding and mannose/lectin specific inhibition actionMucosal vaccine development**Chitosan coated NPs**n.a.Rabies virusImmune system inhibitionImmunization**Peptide coated NPs**BALB/c strainInfluenza A virusCD8^+^ T cells inhibitionNanoparticulate vaccine**Protein coated NPs**BALB/c miceInfluenza A virusantibodydependent\
cell-mediated phagocytosis/cytotoxicityInfluenza vaccine**Amide coated NPs**neuro\
2a cell linesHIVViral transcriptase inhibitionAntiviral therapy**Nano-liposomes**n.a.n.a.Gene silencing actionDrug delivery immunomodulator**Nanomicelle**APC49 Huh7.5Hepatitis C VirusViral cell entry inhibitionAntiviral activity and bioavailable vaccines**AuNPs-carbon nanotubes**n.a.H3N2Peroxidase inhibitionViral detection by colorimetric assay**Polymeric micelle**Male Wistar rats cellHIVViral entry inhibitionOral bioavailable drugs**AuNPs-AgNPs**MDCKH1N1, H3N2Coagulation results from virus surface protein interactionViral inhibition and drug delivery action**Au/FeNPs-carbon nanotubes**n.a.Norovirus, H1N1MagNB mediated enzymeatic signaling inhibitionViral DNA detection**Nanolipid carriers**VK2/E6E7Papilloma virusCell cycle inhibition at G2/M phaseNontoxic viral inhibition**Dendrimer**Vero cells, HELFsHSV-1,2Glycosaminoglycan binding affinity and *in vitro* replication inhibitionm-RNA vaccine[^1]

This review also provides a guide map for the regulation of metabolic enzymes on selected nano-pharmaceuticals, through which the multigenerational effects can be evaluated. This publication is designed to provide vital information on biocompatible nanocarriers, active vs passive targeted drug delivery action of nanomedicines and critically analyze the possible hybrid nano-based therapy for SARS-CoV-2 inhibition. Our current review also highlights the state-of-art molecular fingerprinting techniques of virus identification through advanced biosensing methods, which critically explore integral surveillance and monitoring of novel viral genotypes.

2. Mode of action and biomedical applications of biocompatible nanocarriers {#sec2}
===========================================================================

The different forms of nanomaterials that are mostly used as antiviral agents depend largely on the pathway of drug delivery system, which provide versatile forms of nano-based carriers starting from complex, organic hybrid nanosystems to simple inorganic metallic composites. Nanocapsules, nanocages and nanospheres are categorised under inorganic nanoparticle based systems, though nanocapsules can sometimes come under organic nanocarrier systems based on the their function as therapeutic agents (encapsulated, chemical attachment, adsorbed or dissolved) ([@bib25]; [@bib51]; [@bib21]). [Fig. 1](#fig1){ref-type="fig"} demonstrates the comparative size range of nanoparticles. Whereas, for hybrid nano-based systems, the molecular composition and target specific action of individual engineered nanoparticulate systems play a vital role in drug delivery actions ([Table 1](#tbl1){ref-type="table"}). The mode of action of such nano-based therapeutic agents can be categorised based on the permeability of vasculature (passive targeting for malignancy) or attachment of bioactive ligands to the selective nanotherapeutics ([@bib38]; [@bib23]; [@bib22]).Fig. 1Schematic of the size range of nanoparticles commonly applied in clinical practice as drug delivery agents. (for gene and drug delivery system).Fig. 1

2.1. Role of metallic nanoparticles as *in vivo* (and *in vitro*) drug discharging agents {#sec2.1}
-----------------------------------------------------------------------------------------

The presence of multiple surface binding sites, *in vivo* clinical interaction with the targeted sites, composition based multiple interactions, shape, luminescence and large surface/volume ratio of inorganic nanoparticles render their multifarious biomedical applications ([@bib29]; [@bib16]). The virucidal activity of silver nanoparticles (AgNPs) allows its wider application in the annihilation or amelioration of several viral infections such as Poliovirus type-1, Coxsackievirus B3, influenza A virus, etc. The mode of action of such nanoparticles can be described either through inhibition of CD4-dependent cellular binding/pathogenesis or by covalent linking with sulfhydryl group (virion surface) ([@bib26]; [@bib51]; [@bib18]). The viral internalization can also be prevented by merging nanoparticles with viral genome/core protein that hinders viral replication/attachment, release of viral core into the cytoplasm and governing conformational changes in virus/co-receptor association ([@bib44]; [@bib27]). This type of viral replication inhibitions are quite effective in curing of dsRNA viruses, infectious HSV-2 and bursal disease viruses ([@bib30]; [@bib32]). On the other hand, gold nanoparticles (AuNPs) may also exert their antiviral efficacy through hindering of gp120 fusion to CD4 that are surrounded by capping agents (encapsulated AuNPs) ([Table 1](#tbl1){ref-type="table"}). Hybridized and charged AuNPs render virucidal mechanism after associating with nano-based formulation and mimicking peroxidase enzymatic reaction, where inhibited viral entry is facilitated by blocking of transcription within the host cell ([@bib31]; [@bib40], [@bib41], [@bib42]; [@bib34]).

On the other hand, stabilization of magnetic nanoparticles is often carried out by biocompatible polymers, which helps in the translation of magneto responsive nanoparticulate systems in clinical diagnostics (bio-imaging, bio/resonance-imaging and cell separation). The use of superparamagnetic iron nanoparticles (γ-Fe~2~O~3~/Fe~2~O3/Fe~3~O~4~) is not directly involved in the therapeutics but their indirect application may inhibit viral multiplication even at post-entry cellular level as seen for Zika virus, H5N2 and HCV ([@bib82],[@bib83]; [@bib16]). Photothermal nanotherapy, high refractive index, photocatalytic activities and high solubility properties of titanium nanoparticles (TiNPs) enable them to find their wide antiviral application for bacteriophages and H3N2 viruses ([@bib25]; [@bib35]). The clinical application of functionalized silica nanoparticles (SiNPs) drives the diverse antiviral therapeutics or diagnostics application of nanocarriers in inhibition of HIV, Hepatitis B virus and other recombinant viruses ([@bib37]). Nucleic acid hybridization and fluorescent based virus (viral protein) detection methods are getting popular based on the antiviral efficacy of SiNPs, though their meso to nanoporous biocompatible surfaces allow host/pathogen interaction. The emerging demand for novel antiviral nanotherapeutics triggers the researchers to ponder about immunomodulation and immunization of host cells. These are essential to regulate premature drug release or inhibition of viral entry through *in vivo* biodistribution ([@bib33]; [@bib36]).

Quantum dots (QD), a type of nanosized crystals have excellent nano-based sensing, which allow them to be used as antiviral therapeutics or *in vitro* diagnosis of virulent pathogens, where strong chemical interactions/bonding render their biochemical conjugation with therapeutic molecules ([@bib39]). [@bib40], [@bib41], [@bib42] and [@bib82],[@bib83] have shown that different metallic composition (Pb, Cu, Ga, Zn, Hg) based QD showed target specific actions against HIV-1, human T-lymphotropic virus-1 after their binding with NH~2~- receptor/biotin acceptor. Some researchers have shown that nano-formulations based QDs crossed the BBB (*in vitro* model) along with target DNA and saquinavir antiviral agent, which have been widely utilized as highly active antiretroviral therapy ([@bib40], [@bib41], [@bib42]; [@bib43]).

2.2. Evaluation of organic (and hybrid) nanoparticles as therapeutics and in drug delivery action {#sec2.2}
-------------------------------------------------------------------------------------------------

Organic nanoparticles/nanocarriers (ONP) play an important role in the drug delivery action if the therapeutic compounds are of large sized molecules (\>10--1000 nm). Encapsulation of such nanoagents through specific design/structure render off-target toxicity which is required for target specific action ([@bib46]; [@bib21]). Slow release kinetics and specific target site chemical synthesis have direct influence on ONPs therapeutic competence ([@bib40], [@bib41], [@bib42]; [@bib45]). Polymeric nanoparticles (PNPs) have the clinical potential to carry the target drugs to its core or can coordinate with target molecules on its planar surface (([@bib47]; [@bib50]). Bio-corona formation, ease of biodegradation, strong mechanical/thermal properties of carbon-based nanocarriers (nanorods, nanodots etc.) render their antiviral activities against Respiratory syncytial virus (RSV), HIV-1, Ebola virus etc. ([Table 1](#tbl1){ref-type="table"}). In spite of having broad spectrum activities against antiviral infections, the rate-limiting phase of these carbon materials limits their further biomedical applications.

[@bib53] and [@bib52] have suggested that drug conjugated nanoparticles having excellent antiviral activities can help in the development of an influenza vaccine with Matrix protein 2 (M2e) and Hemagglutinin (HA)/amine functionalized gelatin surface coating. Though more research is required to validate the immunity and protection of cellular genes for such impeccable protein vaccines against infectious virulent pathogens like SARS-CoV-2. With the advancement of medical sciences, the emergence of multifunctional nano-based lipid nanocarriers opens a new door in the field of novel antiviral nanotherapeutics ([Table 1](#tbl1){ref-type="table"}). [@bib59] and [@bib60] have demonstrated that podophyllotoxin, stearic acid/glycol loaded lipid nano-carriers are useful in maintaining *in vitro* slow drug release, non-toxic viral inhibition and hemocompatibility of VK2/E6E7, HeLa cells. Such solid/lipid nanoparticles and other nanolipid carriers can become the exceptional antiviral drug discharging agents for infectious viral pathogens (i.e. HPV, HIV and Hepatitis C virus) ([@bib54]; [@bib58]).

Hyperbranched, monodispersed, easily biodegradable organic dendrimers have gained importance for more than a decade in the field of nanomedicine because they act as targeted carriers for biological systems. The antiviral activity of dendrimers is still under scientific investigations, which may be facilitated through conjugated drug delivery mechanisms ([@bib57]; [@bib55]). The efficacy of such nanoparticulated dendrimer system can be observed for the inhibition of HSV-1/influenza virus, where antibody mediated response/CD8^+^ T cell activation and regulation of gene expressions are achieved through small RNAs inactivation ([@bib64]; [@bib66]).

Niosomes, the non-ionic surfactant based liposome alike organic nanovesicle are getting popular in the advanced biomedical sciences considering their non-immunogenicity and stable optical properties, which make them a suitable carrier of both hydro/lipophilic drug molecules. Excellent bioavailability and controlled release of specific drugs at the targeted sites make such nanocarriers ideal antiviral agents (HSV-1 virus), where nano-niosome was loaded with suitable antiviral drug (acyclovir) ([@bib63]). Improved drug delivery mechanism and suitable drug release kinetics may allow such nanocarriers to be used in infectious virus diseases (nanomicelles) ([Fig. 2](#fig2){ref-type="fig"} ). Supramolecular globular micelles exhibit colloidal stability and super encapsulation potential, which help such polymeric micelles to show antiviral activity *in vitro* as observed from curcumin loaded bioavailable nanoformulations (hepatitis C virus) ([@bib65]). Some researchers used graphene oxides conjugated AdNPs against infectious SARS and bursal viruses, where the drug resistance event after such antiviral efficacy was mediated by selenium nanoparticles (Se-NPs) and/or amantadine (AM) arrangement ([@bib67]; [@bib40], [@bib41], [@bib42]). Diagnosis or detection of such virulent pathogens have been documented by [@bib73] and [@bib72] through thiol-stabilized gold cluster or enteroviruses labeling with cysteine molecule.Fig. 2a and b: Schematic of the Internalization of nanodrugs through the plasma membrane and targeted drug release (a) and transcytosis of nanodrugs through cell barriers (b). Nanoparticulate drug carriers through the cellular and mechanistic establishment crossed the membranes (blood-brain barrier and blood-testis barrier) and with the help of capping agents such as sulfate polysaccharides/polymers undergo multivalent bond interactions with virus glycoproteins (i.e hemagglutinin (HA).Fig. 2

3. A brief overview about antiviral nanomedicines {#sec3}
=================================================

Several nanomedicines (including nanovaccines) are under clinical trial or at least in the stage of commercialization for the cure of infectious viral diseases ([Table 2](#tbl2){ref-type="table"} ). In general, the use of drugs for antiviral therapy is usually employed to target different life cycles of virulent pathogens (i.e. HIV, Ebola virus or HSV-1) ([@bib71]). ALN-RSV01 is a commonly used lipid nanoparticle drug for lower tract respiratory disease, which targets the nucleocapsid "N" gene of RSV virus ([@bib69]; [@bib70]). The size and zeta potential of silver nanoparticles can exert inhibition effects on different Human parainfluenza three virus strains (or on their replication event). The nanocolloidal system of vivagel® is immensely used for the control of Zika virus infection. TKM-130803 is widely used in the treatment of Ebola virus utilizing the concept of RNAi-based therapy for the lipid-based nanosystem. It is well doccumented that for Human Norovirus treatment the employment of gold/copper sulfide core-shell capsid protein binding results into excellent virucidal activity ([@bib84]). On the other hand, nanotrap particles are quite often used in the inhibition of infection of target cells by capturing viral RNA/viral proteins (i.e. influenza virus treatment) ([@bib82],[@bib83]; [@bib81]).Table 2Commercial nanomedicines (or under clinical trial) for the antiviral therapy/treatment (Souce of data: [@bib51]; [@bib44]; [@bib16]; [@bib33]; [@bib34]).Table 2NanomedicinesBiomedical applicationYear/stage of developmentMode of actionDisease indication**Influvac Plus**Virosome vaccine2005Presence of neuraminidase and hemagglutininInfluenza**TKM-HBV**Solid/lipid nanoparticleu.c.eRNAi therapeuticsHBV**Cervisil**SiRNA therapeuticPreclinical evaluationGene silencingHPV**Doravirine**Nanoparticulate formulationu.c.e[a](#tbl2fna){ref-type="table-fn"}Reverse trancriptase inhibitor (non-nucleoside)HIV**DermaVir**Therapeutic vaccineu.c.eDNA immunogen with HIV specific T cell precursorHIV**Inflexal V**Liposome vaccine1997Antigens specific on speherical carriers surfaceInfluenza**Epaxal**Liposome vaccine1999Natural process mimics peroxidasesHAV**Pegasys**PEGylated interferon2002PEGylation control stability of proteinHBV, HCV**Geovax**Antiviral therapyp.eAnkara---Virus alike drug therapySARS-Cov-2**Novavax**Nanoparticulate therapeuticsp.eClinical stage antiviral nanobiotechnologySARS-Cov-2**Fluquit**SiRNA therapeuticp.e[a](#tbl2fna){ref-type="table-fn"}Gene silencingInfluenza**Curevac**Infections virus vaccinep.emRNA techniqueSARS-Cov-2**Peglntron**PEGylated interferon2001PEGylation control stability of proteinHCV**Vivagel**Dendrimeru.c.eDendrimer with sulphonic acid group interactionHSV, HIV[^2]

Intrinsic *in vivo* instability, poor immunogenicity and toxicity, multiple therapeutic and prophylactic approaches can be overcome by nanovaccinology, where cellular and humoral immune response drive the faster uptake of mucosa/gut associated lymphoid tissue. Slow/controlled release of antigens is facilitated by surface modifications of nanovaccines with antibodies/carbohydrates, which results in the target specific immune response by different immune cells. Additionally, their small size and prolonged shelf life help in the faster recognition of the host/receptor immune system (i.e. hepatitis A virus (HAV) and influenza virus), where Epaxal/Exapal is used with immuno targeting agents ([@bib80]; [@bib79]). Non-responsive immune systems, high dose administration, cold-chain transport of parenteral vaccines limit their widespread application in drug therapy particularly for mucosally administered vaccines. The Chitosan/nanoparticle embedded system might be useful for therapeutic proteins or antigens having negative charges, which makes its wider application in vaccination against HBV virus through gene delivery systems ([Table 2](#tbl2){ref-type="table"}). The utilization of mouse model employing humoral and mucosal immune responses helped in the liposome-based vaccine development in case of HepaXen (used for hepatitis A, C, and E), which further utilized the recombinant surface antigen as a prophylactic vaccine ([@bib76]; [@bib74], [@bib75]). The usages of Inflexal V and Influvac as standard virosomal vaccine against influenza virus are getting quite popular considering its active biocompatible and immunogenicity ([@bib78]; [@bib77]). These types of licensed subunit nanovaccines are found quite useful for older, infants and middle-aged group people in terms of nanosafety issue as they mimic natural infections (as seen in [Table 2](#tbl2){ref-type="table"}). A cysteine-guanine rich oligonucleotide combination with extracellular M2e-gold conjugates renders molecular protection for PR8-H1N1 influenza, which was further activated by thiol-gold interactions ([@bib81]; [@bib82],[@bib83]). From the discussion provided here, it is clear that most of the research has been done for influenza virus vaccination but some scanty literature also report vaccine research for Rota/Noro/Ebola virus, HPV, RSV and others ([@bib17]; [@bib14]).

4. Metabolic pathway of nanotherapeutics and their limitations in clinical practice {#sec4}
===================================================================================

Nanoparticles uptake (cellular) process (in nanotherapeutics) are governed by their physico-chemical properties along with cellular membrane characteristics, which may have direct influence on the rate of administered drug dosages and structure of engineered nanoparticles. It is hypothesized that nanoparticles with optimum diameter of ≤50 nm and high surface charge density are quite effective in crossing the cellular membranes for HIV-derived TAT cell penetrating peptides ([@bib77]; [@bib76]). Immunoliposomes and other carbon based nanotubes/nanocarriers play an important role in the activation of the complement pathway of host immune systems to deregulate *in vitro* utilization of NPs ([@bib51]; [@bib40], [@bib41], [@bib42]). Antibodies that are specifically targeted at polyethylene glycol (PEG)/macrogol polymers and PEG-like nanostructures can show independent therapeutic efficacy based on their individual immunotoxicology and risk assessment strategies ([@bib44]; [@bib59]). Experimental findings ([@bib74], [@bib75]; [@bib26]) with nano-based therapeutic agents reveal the urgent requirement of more rigorous scientific investigations to prove their clinical efficiency in reversing the drug resistance event (i.e. H1N1 virus through Se-AM).

Biodegradation process of nanotherapeutics has gained special attention considering uniform biodistribution kinetics and sustained drug release, which are essential for improved drug design process. Distribution, metabolism, absorption, excretion are important pharmacokinetic features, which (rate of biochemical features) are directly governed by hydrophobic/hydrophilic profile and tacticity of the nano-based formulations at *in vitro* level ([@bib57]). Exocytosis process plays a very important role in the clearance of the foreign nanoparticles out of the cell depending on (administered) nanocarriers. It was hypothesized that particles with \<5 nm diameter can excrete through urine, whereas larger particles (\>10 nm) may show their slow release behavior through colon, kidney or liver ([@bib64]). [@bib58] has documented that PEGylated particles exhibit a faster degradation profile compared to cationic particles due to low (or no) agglomeration properties of the former than latter. The large sized nanoparticulates have the tendency to bioaccumulate inside the host cell (HIV, H1N1 infections) and can be a target of mononuclear phagocytic macrophages ([@bib40], [@bib41], [@bib42]; [@bib82],[@bib83]). Thus, removal of extraneous materials (and poor drug material selectivity) from the cellular surface can be overcome by the utilization of bioactive target specific ligands ([@bib40], [@bib41], [@bib42]; [@bib84]).

Cellular uptake of nanotherapeutics can be affected depending on the permeability factor of the biological membranes, which may further limit the endocytotic pathways and therefore restrict wider application of nanotherapeutics in biomedical sectors. Non-specific uptake of nano-based formulations are facilitated by the reticuloendothelial system and macrophages, which results in the prior removal of extraneous materials (and poor drug material selectivity) from the cellular surface ([@bib4]; [@bib6]). This can be overcome by the utilization of bioactive target specific ligands and PEG nanostructured materials as discussed in the usages of polymeric materials for the prevention of clustering of nanoparticles. These are quite useful in the reduction of aggregation properties of such particles in the aqueous phase ([@bib9]). In general, the occurrence, fate, behavior and toxicity profile of nanoparticles largely depend on the steric stabilization factors, which may have direct correlation with the biochemical enzymatic degradation and specific receptors immune response ([@bib16]; [@bib25]). Much more scientific investigations are required in order to get more insights on nanotoxicity, where renal, pulmonary and hepatotoxicity studies are required to build a safety profile of such nanodelivery (therapeutic or diagnostic) agents.

4.1. Nano-based approach for SARS-CoV-2 infection inhibition {#sec4.1}
------------------------------------------------------------

Nano-based formulations have already shown excellent therapeutic approaches for infectious virus detection as mentioned earlier under the section [2](#sec2){ref-type="sec"}. The possible detection and treatment of SARS-CoV-2 have been documented elsewhere by [@bib60] and [@bib74], [@bib75], where a molecular modeling approach was undertaken along with FMDV 3Dpol. The wider application of carbon based nanomaterials has been documented by [@bib74], [@bib75] and [@bib44] for the inactivation of H3N2, H5N1 and HBV. Oxidation of viral proteins that generate reactive oxygen species often function as an initiation inhibitor for the prevention of FMDV RNA synthesis that might promote mutations in RdRps through hydrophobic interactions ([Table 3](#tbl3){ref-type="table"} ). Viral binding of gp120 and CD4 through host cell surface receptor and photothermal medium (regulation of cell pH) can be achieved *in vitro* (for HIV-1 virus with AuNPs) ([Fig. 3](#fig3){ref-type="fig"} ). SARS-CoV-2 nsp12 (along with polymerase, interface and NiRAN domain) conserve the sequence variations in the NTP-binding motifs through N-terminal region of nsp12 (current CoV-2 strain) ([@bib74], [@bib75]; [@bib58]). Inhibition of virus entry can be mediated by virus surface glycoprotein interaction with nanomedicines (i.e. Nipah virus *in vitro* treatment) (([@bib16] and [@bib70]), where G and F surface proteins were targeted by lipid based nanoparticles. Conservative binding of viral genome with TiNPs, p53 phosphorylation, modulation of genetic engineering of viral vectors/transcription and selenium embedded nanotherapeutics can be effectively used for SARS-CoV-2 control ([Fig. 3](#fig3){ref-type="fig"}).Table 3Diagnostic approaches adopted for the different species of genus *Betacoronavirus* by the developed and developing countries according to the preliminary laboratory clinical trials (Souce of data: [@bib1]; [@bib34]; [@bib78]; [@bib77]; [@bib82],[@bib83]; [@bib81]).Table 3Species in the BetacoronavirusOrigin of clinical samplesYear/stage of developmentSalient findingsSensitivity/specificity**SARS-CoV**Real-time fluorescent PCR (Hong Kong)2003Enhanced real-time PCR method was effectiveThreshold sensitivity**SARS-CoV**Blot assay with N195 protein (Singapore)2003\>90% of the specificity observedThreshold sensitivity**SARS-CoV**Biochemical assay (Taiwan)2004Neutralization test was found suitable in terms of sensitivity observedThreshold sensitivity**MERS-CoV**RNA amplification kit (Japan)2014RT-PCR was able to detect even at lower detection range of viral RNA copies (\~1.6--2.0)Threshold sensitivity**MERS-CoV**RNA detection kits based on rRT-PCR (Korea)2016Kits were able to provide good specificity and sensitivity clinical specimens having high inhibition potentialThreshold sensitivity**MERS-CoV**upE and ORF1a gene based PCR (Korea)2017RT-iiPCR\
Assays and RT-qPCR assays were correlatedThreshold sensitivity**SARS-CoV**RT-PCR biochemical assay (Canada)2004Natural process mimics peroxidasesBroad dynamic detection ranges**SARS-CoV**Real time qRT-PCR (Hong Kong)2005Immunocromatographic test and ELISA test was quite useful with specificity of 95%Broad dynamic detection ranges**MERS-CoV**rRT-PCR based assay (Iran)2015non-nested RT-PCR assay with Cor-p-F2 and Cor-p-R1 was found suitableBroad dynamic detection ranges**SARS-CoV-2**rRT-PCR based assay (Germany)2020RdRp gene assays and E gene provided satisfactory resultsBroad dynamic detection ranges**SARS-CoV-2**RT-PCR test Kit based assay (U.K.)2020Broad dynamic detection rangeBroad dynamic detection ranges**SARS-CoV-2**RT-PCR test Kit based assay (China)2020Metagenomics sequencing kit provided good resultsBroad dynamic detection ranges**SARS-CoV-2**RT-PCR test Kit based assay (U.S.A.)2020Commercial process gave good resultsThreshold sensitivity**SARS-CoV-2**Enzyme-assisted nanocomplexes for nucleic acids detection (Singapore)2020High-throughput screening enabled monitoring of evolutionBroad dynamic detection ranges**SARS-CoV-2**Convalescent plasma therapy (India)2020Under pre-clinical trial and not licensed for diagnostic\
proceduresThreshold\
Sensitivity (more clinical trials/observations are required)Fig. 3Conceptual diagram of host/receptor cell infection after attachment with coronaviruses (SARS-CoV-2) and signaling pathways of virulent pathogens render overexpression of genetic and serological markers that help in the biochemical balance of cell survival and cell death after virulence. Nanodrugs can pass the physiological and anatomical barriers of the respiratory system and can act as anticoagulants.Fig. 3

On the other hand, oligonucleotides based nanocomposite binding, silencing of viral replication with niosomes/liposomes, polyadenylated and capped lineage B of β-CoVs sequencing etc. can be used to have more insights on nanoparticulate drug carriers against SARS-CoV-2 ([@bib14]). Much more clinical trials are needed to build strong hypotheses on nano-based antiviral therapy that can address subgenomic and individual RNAs translation into replication-transcription complexes ([Table 3](#tbl3){ref-type="table"}). Phylogenetic analysis of coronavirus-encoded papain-like proteases renders examples of antiviral targets, where some antiviral drugs such as 5-fluorouracil, remdesivir, ribavirin and other repurposed drugs can be conjugated to exert prophylactic/therapeutic action at the epithelial cells ([@bib25]; [@bib6]). Blocking of the secretion of antiviral signaling molecules and the reduced expressions of the pattern recognition receptors may further help in the nanodrug therapy with known virus infection and histopathological features ([Fig. 3](#fig3){ref-type="fig"}). For the recent SARS-CoV-2 outbreak the utilization of genetic segments i.e Recombinant DNA (rDNA) will be helpful in the development of nanovaccines along with other subunit and virus like particles derived vaccines, etc. Angiotensin converting enzyme 2 (ACE2) is commonly found in the cellular matrices of small intestine and lung, which may hinder the action of nanotherapeutics considering the mode of action of SARS-CoV-2 ([@bib17]; [@bib9]).

Researchers ([@bib11]; [@bib30]) have undergone several clinical trials for the real curative solution for SARS and MERS, but it was reported that social, economical and clinical limitations influenced the development of effective antiviral therapy in nanodrugs. Most of the clinical trials were in experimental stages (*in vitro phase*) and some of them have received green signals as a post-exposure prophylaxis (i.e.advanced drug treatment options for SARS-CoV) ([Table 3](#tbl3){ref-type="table"}). Many researchers ([@bib1]; [@bib34]) have found that corticosteroids with interferon alfacon-1 may have effective antiviral actions for such group of coronaviruses having RNA-dependent RNA polymerases. [@bib23] and [@bib24] have reported that niclosamide, novavax and geovax might have the potential to inhibit virus-cell entry and virus replication. They have documented that more clinical trials are needed to validate the clinical actions of new generation nanotherapeutics that might also have some immunomodulatory or immunostimulatory actions.

5. Role of antiviral nanotherapy in infectious virus control {#sec5}
============================================================

Viruses as obligate intracellular infectious pathogens interact with host cells involving different types of receptor/ligand biochemical interactions. The prime requirement of drug design mainly depends on several biological factors such as replication dynamics, sub-cellular complex biochemical interaction, the chances of latent infection and development of drug resistance events ([@bib10]; [@bib9]). The use of nanotechnology has gained popularity in medical oncology though it has been reported that some chemotherapeutic agents do not possess target specific actions for malignant cells ([@bib30]; [@bib31]). The mode of action of such nano-based therapeutic agents can be categorised based on the permeability of vasculature or attachment of bioactive ligands to the selective nanotherapeutics (active targeting for virus infections) ([@bib33]; [@bib34]).

Specific subcellular regions or particular organelles trigger the mode of action of nanodrugs/nanocarriers based on the attachment potential of such agents with specific host/receptor cells with the nuclear localization signals ([Fig. 2](#fig2){ref-type="fig"}). Strand transfer reactions of the infectious virus are prevented by integrase inhibitors action, which on the other hand drive the disease drug development after traversing the inaccessible biological compartments ([@bib32]; [@bib23]). The drug delivery actions (at all concentrations) are often controlled by BBB compartments as observed for HIV infections, where neurological disorders (due to replications) can result in latency in the brain in the absence of antiretroviral (ARV) drugs. ARV conjugated nanoparticles are quite useful in the control of viral replications due to their small size overcoming the barriers of targeted and specific cell site actions, which provides efficient delivery of the nanoformulations at high drug payload ([@bib27]; [@bib40], [@bib41], [@bib42]). These types of molecular mechanisms will be useful in decreasing the probability of antiretroviral-drug resistance events for the therapeutic applications of nanoformulations in the clinical drug delivery and diagnostics of HIV/H5N1/HBV/HSV ([@bib23]; [@bib43]).

6. Conclusions {#sec6}
==============

In the present review, we have synthesized and critically analyzed the available literature data on nanobiotechnology aspects of biomedical research and highlighted the occurences, mode of action and limitations of a suite of nanotherapeutics commonly used in the treatment of viral infections. The pivotal conclusions and suggestions derived out of this review are summarized below:a)Over the past decades, a bunch of literature have been published on the conventional immune mediated antiviral drugs and vaccines, but little is known about the functionalized nanoparticle-based drug delivery systems for the treatment of SARS-CoV-2. Therefore, the present review provides deep insights on the feasibility of controlling of COVID-19 outbreaks by such nanotherapeutic agents.b)*In vitro* antiviral activity and optimized dosing of nano-based formulations have been found to be effective against hepatitis, HIV, Ebola and influenza viruses, where co-ordination with suitable targeting multivalent ligands enables such nanocarriers to bind with target host-receptor cells.c)The enhancement of drug efficiency (and gene delivery)/therapies are commonly applied to a spectrum of diseases (i.e. HPV, RSV, Noro and Ebola virus) that can be reliable and cost-effective methods for *in vivo* utilization of immunoliposomes and carbon nanotubes. These are useful for adults, children and middle aged people considering their non-toxic, good immunogenicity, stability and good biological profile.d)To understand the proper mode of action of nano-based strategies against SARS-CoV-2, pathogenesis of the novel coronavirus needs to be evaluated. The utilization of nanoparticles for nanomedicine/nano-based cell therapy will be useful in blocking the downstream signaling actions of pegylated α which will otherwise impart resistance to infected cells.
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[^1]: n.a\*- Not applicable, AuNPs-Gold Nanoparticles, AgNPs-Silver Nanoparticles, FeNPs-Iron Nanoparticles, SiNPs-Silica Nanoparticles, TiO~2~- Titanium nanoparticles, GO-Graphene oxides.

[^2]: p.e-preclinical evaluation, u.c.e-under clinical evaluation, HAV- hepatitis A virus, HIV- human immunodeficiency virus, HBV- hepatitis B virus, HPV- human papillomavirus, HCV- hepatitis C virus, HSV- herpes simplex virus.
